程序性死亡配体 1（PD-L1）表达和纤维母细胞生长因子受体 1（FGFR1）扩增与 III/IV 期肺鳞状细胞癌（SQC）。
Programmed cell death-ligand 1 (PD-L1) expression and fibroblast growth factor receptor 1 (FGFR1) amplification in stage III/IV lung squamous cell carcinoma (SQC).
机构信息
Respiratory Department Division One, Shanxi Province Tumor Hospital, Taiyuan, China.
Department of Thoracic Medical Oncology, The Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing Cancer Hospital, Beijing Institute of Cancer Research, Beijing, China.
出版信息
Thorac Cancer. 2017 Mar;8(2):73-79. doi: 10.1111/1759-7714.12399. Epub 2016 Dec 23.
BACKGROUND
This study was conducted to explore programmed cell death-ligand-1 (PD-L1) expression and fibroblast growth factor receptor 1 (FGFR1) amplification in stage IIIB/IV lung squamous cell carcinoma (SQC). Correlations between PD-L1 and FGFR1, and with clinicopathological characteristics, efficacy of platinum-based chemotherapy, and prognosis were analyzed.
METHODS
One hundred and twenty-eight consecutive stage III/IV SQC patients were enrolled in this study from 2009 to 2014. Seventy-eight patients received platinum-based chemotherapy. Immunohistochemistry was used to assess PD-L1 expression and fluorescence in situ hybridization was applied to detect FGFR1 amplification.
RESULTS
PD-L1 expression was detected in 61.7% (79/128) of lung SQC patients. Smokers had significantly higher PD-L1 expression rates than non-smokers (66.1% vs. 44.0%, P = 0.042, respectively). The objective response and disease control rates for platinum-based chemotherapy were not significantly different between PD-L1 negative and positive patients (43.3% vs. 36.2%, P = 0.434; 80.0% vs. 78.7% P = 0.840, respectively); however, overall survival in PD-L1-negative patients was significantly longer than in PD-L1-positive patients (41.5 vs. 19.3 months, P = 0.001). Twenty-five percent (32/128) of patients displayed FGFR1 amplification, with a lower rate in stage III patients compared to stage IV (17.1% vs. 36.5%, P = 0.013, respectively). There was no significant difference in FGFR1 amplification levels between overall response, disease control or overall survival rates. No correlation was observed between PD-L1 expression and FGFR1 amplification ( P = 0.916).
CONCLUSION
PD-L1 expression may function as a prognostic factor in Chinese stage III/IV SQC patients. FGFR1 amplification is more prevalent in late stage SQC patients but does not predict chemotherapy response. There is no apparent correlation between PD-L1 expression and FGFR1 amplification.
背景
本研究旨在探讨程序性死亡配体 1（PD-L1）表达和成纤维细胞生长因子受体 1（FGFR1）扩增在 IIIB/IV 期肺鳞状细胞癌（SQC）中的作用。分析了 PD-L1 与 FGFR1 之间的相关性，及其与临床病理特征、铂类化疗疗效和预后的关系。
方法
本研究纳入了 2009 年至 2014 年期间的 128 例连续的 IIIB/IV 期 SQC 患者。其中 78 例患者接受了铂类化疗。采用免疫组织化学法检测 PD-L1 表达，荧光原位杂交法检测 FGFR1 扩增。
结果
在 128 例肺 SQC 患者中，检测到 61.7%（79/128）的患者存在 PD-L1 表达。吸烟者的 PD-L1 表达率明显高于不吸烟者（66.1%比 44.0%，P=0.042）。PD-L1 阴性和阳性患者的铂类化疗客观缓解率和疾病控制率无显著差异（43.3%比 36.2%，P=0.434；80.0%比 78.7%，P=0.840）；然而，PD-L1 阴性患者的总生存期明显长于 PD-L1 阳性患者（41.5 比 19.3 个月，P=0.001）。25%（32/128）的患者存在 FGFR1 扩增，其中 III 期患者的 FGFR1 扩增率低于 IV 期（17.1%比 36.5%，P=0.013）。FGFR1 扩增水平与总体反应率、疾病控制率或总生存率之间无显著差异。PD-L1 表达与 FGFR1 扩增之间无显著相关性（P=0.916）。
结论
PD-L1 表达可能是中国 IIIB/IV 期 SQC 患者的预后因素。FGFR1 扩增在晚期 SQC 患者中更为常见，但不能预测化疗反应。PD-L1 表达与 FGFR1 扩增之间无明显相关性。
Zotero 插件